Corporate Presentation. June 2018
|
|
- Clare Walsh
- 5 years ago
- Views:
Transcription
1 Corporate Presentation June 2018
2 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, clinical development plans, anticipated milestones, product candidate benefits, potential market size, product adoption, market positioning, competitive strengths, product development, and other clinical, business and financial matters. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially. Risks and uncertainties include, but are not limited to, our limited operating history, our need for additional financing to achieve our goals, our dependence on our lead product AR101, the need for additional clinical testing of AR101, uncertainties relating to the regulatory process, uncertainties relating to the timing and operation of clinical trials, potential safety issues, possible lack of market acceptance of our product candidates, the intense competition in the biopharmaceutical industry, our dependence on exclusive third-party suppliers and manufacturers, and limitations on intellectual property protection. A further list and description of these risks, uncertainties and other factors can be found in our report on Form 10-Q filed on May 8, Copies of this filing are available online at or Any forward-looking statements made in this presentation speak only as of the date of the presentation. We do not undertake to update any forward-looking statements as a result of new information or future events or developments. 2
3 Aimmune Therapeutics: The Food Allergy Therapeutics Company Our Urgent Priority Provide kids, young adults and their families protection, peace of mind, and freedom from food allergies. 3
4 There Is a Large and Growing Need for Food Allergy Treatments Responsible for 200,000 visits to U.S. emergency rooms each year 1 Cost American families ~ $25 billion a year, with ~ $4 billion attributed to direct medical expenses 2 Living with food allergies means living with constant risk and uncertainty Food allergies can lead to life-threatening reactions There are no approved treatments for food allergies >30M 4 1. Clark S et al. J Allergy Clin Immunol. 2011;127(3): Gupta R, et al. JAMA Pediatr. 2013;167(11): National Institute of Allergy and Infectious Diseases, National Institutes of Health. Retrieved from 4. United States Census Bureau Quick Facts (2015 estimates). 5. Gupta RS, et al. Pediatrics 2011;128(1):e EAACI. Food Allergy & Anaphylaxis Public Declaration. People have food allergies in the United States and Europe 3-6
5 Aimmune was founded to address the collective call to action from food allergy leaders and patient advocates for the development of an FDA-approved biologic oral immunotherapy (OIT) for the treatment of food allergies. 5
6 Aimmune Is Developing the CODIT Approach to Treat Food Allergies Characterized Oral Desensitization ImmunoTherapy A standardized oral immunotherapy (OIT) protocol with precise oral dosing FDA-regulated biologic products Training and education Goal: Gradually increase the body s ability to tolerate larger amounts of allergenic food proteins without mounting an allergic reaction. ~12 visits to the allergist twice a month for 6 months and daily at-home dosing between visits Convenient daily dose taken with food 6
7 Our Pipeline of CODIT Treatments for Food Allergies Biologic Drug Products and Protocols Pre-IND Phase 2 Phase 3 Next Milestone AR101: Peanut Allergy Fast Track and Breakthrough Therapy Designation (Ages 4-17) PALISADE Core Efficacy and Safety Study (Ages 4-55) RAMSES Real-World Experience Study (U.S. / Canada) Completed Met Primary Endpoint, Ages 4-17* BLA by YE 2018 MAA by 1H 2019 Data 2H 2018 AR101 ARTEMIS European Trial Data 1Q 2019 ARC004 PALISADE Roll-Over Study Data Cut 2H 2018 ARC005 Pediatric Study Initiate P3 2H 2018 AR101 + Adjunctive Dupilumab Initiate P2 2H 2018 AR201: Egg Allergy Initiate 2019 File IND 2018 AR301: Walnut Allergy Initiate 2019 File IND *Primary Endpoint: The proportion of patients who could tolerate at least 600 mg of peanut protein (~2 peanuts) in an exit double-blind, placebo-controlled food challenge
8 Industry Leaders Share Our Vision Scientific Discovery and Innovation Pipeline Expansion Building AR101 Value Clinical collaboration (Oct 2017) with Aimmune Regeneron/Sanofi Joint Development Committee Phase 2 of AR101 with adjunctive dupilumab expected to start in 2018 * Plan to explore sustained unresponsiveness in peanut allergy $145M strategic equity investment (Nov 2016) $30M participation in equity financing (Feb 2018) Two-year working collaboration Aimmune retains full global rights to all CODIT pipeline assets, including AR101 Leading handler, processor, and exporter of peanut and tree nuts Exclusive supply of AR101 starting material through 2034 Alliance focused on protecting people with peanut allergies Equity stake in AIMT 8 *Regeneron will sponsor the trial, with Aimmune to provide clinical supply of AR101 and food challenge materials
9 Aimmune s First CODIT Focus: Peanut Allergy
10 There Is a Large and Growing Need for Peanut Allergy Treatments Prevalence in the United States and EU5 Millions of Patients (Ages 1 to 55) 8.2M U.S. Ages 4 to M 1.4M 6.4M 1.7M 7.3M 1.8M 2.0M EU5 Ages 4 to M 1.2M 1.3M 1.4M 2015E 2020F 2025F 2030F 10 Sources: Gupta (2011, 2013), Avery (2003), Cummings (2010), Sicherer (2010), Venter C (2010), Hourihane JO (2007), Nicolaou (2010), World Bank, Aimmune internal analysis
11 Avoiding Peanut Protein Is Very Difficult Peanut Protein Can Be Difficult to Detect People With Peanut Allergies Can Be Sensitive to the Amount of Peanut Protein Found in a Fraction of a Peanut Kernel 1,2 One Accident Can Be Fatal Allen K, et al. Allergen reference doses for precautionary labeling (VITAL2.0): Clinical implications. J Allergy Clin Immunol. 2014; 133(1): Deschildre A, et al. Peanut-allergic patients in the MIRABEL survey: characteristics, allergists dietary advice and lessons from real life. Clinical & Experimental Allergy; 46:
12 There Is a Significant Burden of Living with Peanut Allergy Constant Risk and Uncertainty Due to Likelihood of Reaction to Accidental Exposure Peanut Allergy Can Substantially Diminish Quality of Life of Patients and Their Families ~40% of Patients Experienced Anaphylaxis After Already Being Made Aware of Their Condition 1 83% 76% There s always that Reported that Peanut Allergy Makes it Hard to Attend Social Events 2 Reported that Peanut Allergy Interferes with Quality of Life Overall 2 fear when you can t be with her. You don t want to roll the dice and take any chances. -Caregiver Aimmune proprietary market research based on anaphylaxis codes (not accounting for physician under-coding) over an average 3-year observation period; Symphony Health Patient Claims (Jan 2011-Jun 2017) 2. MyFoodAllergyTeam Survey (N=129, conducted April 2017)
13 Therapeutic Goals of AR101 Align With What Patients Want Bite-Proof level protection e.g., a child s bite of a peanut butter sandwich (~2 peanuts) No or reduced reactions Certainty Market Research 1 Shows Parents and Patients Want: We Designed PALISADE Phase 3 to Evaluate: Ability to tolerate at least 600 mg (~2 peanuts) 2 Reduced symptom severity Daily oral maintenance dosing with AR101 Rapid effect Efficacy outcomes after ~12 months on therapy Based on qualitative interviews with 200+ allergists, patients and physicians, quantitative surveys with >300 allergists and >400 parents in the United States and EU 2. Defined as successful consumption of at least 600 mg peanut protein with no more than mild symptoms in an exit double-blind, placebo-controlled food challenge 3. ~6 months up-dosing and ~6 months maintenance
14 Phase 3 PALISADE Results (Ages 4 17) Primary and Key Secondary Efficacy Endpoints Met 600 mg peanut protein is approximately 2 peanuts Primary endpoint: Difference between groups = 63% (95% CI: 53,73) p< Safety Over 12 Months of Treatment More than 111,000 doses of AR101 administered (307 patient-years of exposure) No suspected, unexpected serious adverse reactions No life-threatening adverse events 4 (1.1%) subjects experienced treatment-related serious adverse events One case of severe anaphylaxis (subject withdrew from the trial) 6.7% gastrointestinal adverse events that led to discontinuation AR101 (n=372) Placebo (n=124) One case of eosinophilic esophagitis (resolved after study discontinuation) *Responders based on Intent-to-Treat, defined as subjects who tolerated each dose level with no more than mild symptoms at the exit double-blind, placebo-controlled food challenge; p< for treatment difference >15% 14 Jones S, et al. AAAAI 2018
15 Longitudinal Change in Highest Tolerated Dose ITT Analysis: Median Amount of Peanut Protein Tolerated in Entry & Exit DBPCFCs 1000 mg 10 mg 10 mg 30 mg 15 ITT: Intent-to-Treat Population, 4-17 age group DBPCFCs: Double-Blind, Placebo-Controlled Food Challenges Jones S, et al. AAAAI 2018
16 Subjects Having Symptoms (%) Subjects Having Symptoms (%) AR101 Symptom Severity at Exit DBPCFC Placebo AR101 Subjects Attempting Dose Subjects Attempting Dose Symptom Severity Scoring Key None Mild Moderate Severe Compared to placebo, the AR101 group developed fewer moderate and severe symptoms 16 DBPCFC: Double-Blind, Placebo-Controlled Food Challenge Jones S, et al. AAAAI 2018
17 Responders % Exploratory Analysis of Similarities Across Age Groups Completers: Subjects Across Age Cohorts Who Tolerated 600 mg at Exit DBPCFC % 82.8% 85.0% AR101 Placebo % 3.1% (n=84) Ages 4-11 (n=281) (n=197) (n=99) (n=20) (n=32) Ages (n=131) 15.4% (n=13) Single Highest Tolerated Dose of 600 mg Ages (n=33) * * On an intent-to-treat basis, the p-value was p= DBPCFC: Double-Blind, Placebo-Controlled Food Challenge Responders defined as subjects who tolerated each dose level with no more than mild symptoms at the exit DBPCFC
18 Efficacy Across All Ages Is Important as Peanut Allergy Does Not Usually Resolve With Age 1 Ages Estimated Percent of Total Peanut- Allergic Patients % 27% 10% 46% PALISADE Phase 3 trial primary endpoint analysis conducted in 4-17 age group 2. Estimates based on Aimmune proprietary market research
19 Potential AR101 Commercial Launch to Focus on U.S. Allergists
20 Allergists Are Ready for an FDA-Approved Oral Immunotherapy ~5,000 Allergists in the United States ~75% Surveyed Would Prescribe an FDA-Approved Oral Immunotherapy Survey of 442 members of The American Academy of Allergy, Asthma & Immunology (AAAAI) reported by Greenhawt M and Vickery B, Allergist-Reported Trends in the Practice of Food Allergen Oral Immunotherapy. J Allergy Clin Immunol Pract (2015); 3(1):
21 Many Allergists View Food Allergy Therapeutics as Very Important to the Future Viability of Their Practices Food-allergic patients tend to have several co-morbidities due to the Atopic (Allergic) March The Allergic March Phase 3 PALISADE (Ages 4-17) 72% history of anaphylaxis 53% asthma 66% multiple food allergies 72% allergic rhinitis Eczema Food Allergy Rhinitis Asthma AR101 and Other CODIT Treatments May Help Anchor a Deep Long-Term Relationship Between Allergist and Patient at an Early Age 21
22 If Approved AR101 Would Fit Well With Current Allergy Practice Additive to Practice Allergists surveyed believe their practices today have the capacity to treat patients with AR101. Infrastructure Exists Practice management with AR101 should be similar to allergy shots for environmental allergies. Reimbursement Expected Physicians services for multiple office visits during up-dosing should be reimbursed as a medical benefit. 22 Based on Aimmune proprietary market research
23 Community Allergists Will Drive AR101 Adoption, If Approved Importance to Practice Dynamics Reimbursement for Services Matter Clinic Time Is Valuable Allergy Shot Experience Is Leveraged Excited for a New Patient Population Practice Settings Academia Community Practice 23 Based on Aimmune proprietary market research
24 AR101 Has the Potential to Capture Meaningful Market Share ~5,000 U.S. Allergists Target: 3,000 practices at peak ~1.6M U.S. Kids and Teens with Peanut Allergy Target: 150,000 up-dosed at peak >$1B Estimated U.S. Market Opportunity for AR101 with Sales Force of < Estimates based on Aimmune proprietary market research
25 Strong Proprietary Position with AR101 for Peanut Allergy Biologic Data Exclusivity (12 years in the U.S.) Issued Patents Covering Formulation and Manufacturing/ Analytics Exclusive Commercial Supply Agreement Manufacturing Expertise, Trade Secrets and Know-How First Mover Advantage and Building a Trusted Brand 25
26 CODIT Pipeline Drives Long-Term Value
27 Large Opportunities in Food Allergies Beyond Peanut Egg Walnut Multi-Nut Milk In 2025 there may be ~ 1.7M egg allergic patients across US, EU5, China and Japan Majority of patients ages 1-4 years old Most common food allergy in China and Japan High prevalence that has significantly increased in the last ~20 years In the US, ~0.5% of children and ~1% of adults are walnut allergic Severe and unpredictable allergy; usually lifelong Incidence of multi-nut allergy is high among people who are tree nut allergic Collective prevalence approaches that of peanut allergy ~ 2.5% of children under three years old are allergic to milk Failure to thrive challenges High desire to address given milk is viewed as a nutritional requirement and very difficult to avoid 27 Estimates based on Aimmune proprietary market research
28 Event-Rich Year Ahead!
29 Anticipated Milestones H1 $332M We Are Well Capitalized to Deliver on Our Goals 1 ARTEMIS (EU) Ph3 Enrollment Complete (Mar) Additional PALISADE Ph3 data at EAACI (May) H2 Initiate AR101 + Dupilumab Trial (Regeneron/Sanofi) RAMSES Phase 3 Data ARC004 (PALISADE Follow-On) Ph3 Data cut completed Initiate AR101 Pediatric Trial (ARC005) BLA Submission for AR101 Submit IND for AR201 Egg H1 BLA submission accepted and PDUFA date set ARTEMIS Ph3 Data Initiate AR201 Ph2 MAA Submission for AR101 IND Submission for AR301 Walnut H2 Potential Ad Comm for AR101 Potential U.S. Approval of AR101 Potential US Commercial Launch Initiate AR301 Walnut Ph2 Trial $332M Cash, cash equivalents and investments as of 03/31/
30 Aimmune Is Leading the Quest for Food Allergy Therapeutics Patient-Focused A treatment paradigm in food allergy Potentially the first FDA-approved medicine for peanut allergy Driving the development of new medicines for food allergy CODIT AR101 Innovation 30
31 We Invite You to Learn More
32 Aimmune Executive Team Leader Role Experience Stephen Dilly, MBBS, PhD* Chief Executive Officer Daniel Adelman, MD Chief Medical Officer Sue Barrowcliffe Eric Bjerkholt Jeffrey Knapp* Mary Rozenman, PhD General Manager of Europe Chief Financial Officer Chief Operating Officer SVP, Corporate Development and Strategy Experienced Team of Drug Developers with 30+ NDAs, BLAs and MAAs Doug Sheehy General Counsel and Secretary William Turner SVP, Global Regulatory and Quality 32 Dr. Jayson Dallas will assume the role of President and CEO on June 19, 2018, and Dr. Stephen Dilly will become Special Advisor to Aimmune through 2018; Jeff Knapp will depart Aimmune on July 6, 2018.
33 Aimmune Top Shareholders 33 FIRM NAME % OS POSITION Nestle Health Science US Holdings, Inc ,489,584 Longitude Capital Management Co., LLC ,013,134 T. Rowe Price Associates, Inc ,492,077 Foresite Capital Management, LLC ,254,965 Fidelity Management & Research Company ,615,171 Aisling Capital, LLC ,240,000 Wellington Management Company, LLP ,061,192 Eventide Asset Management, LLC ,564,983 Eagle Asset Management, Inc ,400,482 Palo Alto Investors LP ,356,514 AllianceBernstein L.P ,331,941 Point72 Asset Management, L.P ,079,900 Explore Holdings, L.L.C ,024,117 Great Point Partners, LLC ,579 Emerald Advisers, Inc ,471 Balyasny Asset Management LP ,875 Deerfield Management Company, L.P ,210 Baker Bros. Advisors LP ,908 Victory Capital Management Inc ,641 Morgan Stanley Wealth Management ,634 TLP Trading, LLC ,000 Adage Capital Management, L.P ,000 Franklin Advisers, Inc ,900 Loomis, Sayles & Company, L.P ,320 Dilly (Stephen George Ph.D.) ,008 Jennison Associates LLC ,866 Vivo Capital, LLC ,872
Corporate Presentation. October 2018
Corporate Presentation October 2018 Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among
More informationAccording to a post-hoc analysis, 62.6% of patients receiving Viaskin Peanut showed an increase in their eliciting dose at 12 months of treatment
Montrouge, France, February 22, 2019 DBV Technologies Announces Publication of Detailed Phase III Trial Results Evaluating Viaskin Peanut as a Novel Treatment for Peanut Allergy in The Journal of the American
More informationPrimary Prevention of Food Allergies
Primary Prevention of Food Allergies Graham Roberts Professor & Honorary Consultant, Paediatric Allergy and Respiratory Medicine, David Hide Asthma and Allergy Research Centre, Isle of Wight & CES & HDH,
More informationViaskin Peanut Highlights. Press Release Montrouge, France, March 5, 2017
Press Release Montrouge, France, March 5, 2017 Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut
More informationFOOD ALLERGY AND ANAPHYLAXIS PROGRAM
FOOD ALLERGY AND ANAPHYLAXIS PROGRAM Phoebe and Paul (above), both living with nut allergies, are among the many Canadian children that the SickKids Food Allergy and Anaphylaxis Program will benefit. Parents,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationPediatric Food Allergies: Physician and Parent. Robert Anderson MD Rachel Anderson Syracuse, NY March 3, 2018
Pediatric Food Allergies: Physician and Parent Robert Anderson MD Rachel Anderson Syracuse, NY March 3, 2018 Learning Objectives Identify risk factors for food allergies Identify clinical manifestations
More informationASIA FRANCHISE BUSINESS UNIT (FBU) Siddharth Varma, Managing Director
ASIA FRANCHISE BUSINESS UNIT (FBU) Siddharth Varma, Managing Director Yum! Asia FBU: Partnering For Growth China = 3,900 units Thailand = 480 units Asia FBU = 4,500+ units Asia FBU Asia FBU: Collection
More informationILSI Workshop on Food Allergy: From Thresholds to Action Levels. The Regulators perspective
ILSI Workshop on Food Allergy: From Thresholds to Action Levels The Regulators perspective 13-14 September 2012 Reading, UK Sue Hattersley UK Food Standards Agency Public health approach Overview Guidance
More informationRaymond James 33 rd Annual Institutional Investors Conference March 5, DineEquity, Inc. All rights reserved.
Raymond James 33 rd Annual Institutional Investors Conference March 5, 2012 Forward-Looking Information Statements contained in this presentation may constitute forward-looking statements within the meaning
More informationHow to avoid complete elimination
How to avoid complete elimination Yu Okada 1, 2), Noriyuki Yanagida 2), Sakura Sato 2), Motohiro Ebisawa 2) 1) Department of Family Physician, Kameda Family Clinic Tateyama, Chiba, Japan 2) Department
More informationWHY IS THERE CONTROVERSY ABOUT FOOD ALLERGY AND ECZEMA. Food Allergies and Eczema: Facts and Fallacies
Food Allergies and Eczema: Facts and Fallacies Lawrence F. Eichenfield,, M.D. Professor of Clinical Pediatrics and Medicine (Dermatology) University of California, San Diego Rady Children s s Hospital,
More informationFood Allergy Community Needs Assessment INDIANAPOLIS, IN
Food Allergy Community Needs Assessment INDIANAPOLIS, IN Conducted by: Food Allergy Research & Education (FARE) Food Allergy Research& Education FARE s mission is to improve the LIFE and HEALTH of all
More informationFood Allergies Among Children -
Food Allergies Among Children - Growth, Treatment, Prevention and a Challenge for the Food Industry Steve L. Taylor, Ph.D. Food Allergy Research & Resource Program University of Nebraska Food Navigator
More informationBeth Strong, RN, FNP-C The Jaffe Food Allergy Institute Mount Sinai School of Medicine New York 2/23/13
Beth Strong, RN, FNP-C The Jaffe Food Allergy Institute Mount Sinai School of Medicine New York 2/23/13 I do not have any financial disclosure to report Why Challenge? To confirm that the suspected food
More informationNorth America Ethyl Acetate Industry Outlook to Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants
North America Ethyl Acetate Industry Outlook to 2016 - Market Size, Company Share, Price Trends, Capacity Forecasts of All Active and Planned Plants Reference Code: GDCH0416RDB Publication Date: October
More informationUnderstanding Anaphylaxis in Schools
For some parents and guardians, sending a child with potentially life-threatening (severe) allergies off to school can feel like a daunting task. Successfully transitioning a child into school requires
More informationFood Allergies on the Rise in American Children
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/hot-topics-in-allergy/food-allergies-on-the-rise-in-americanchildren/3832/
More informationSt. Agnes Catholic Primary School Highett Anaphylaxis Policy
1. Introduction St. Agnes Catholic Primary School Highett Anaphylaxis Policy This policy has been prepared to assist in preventing life threatening anaphylaxis and is based on advice from the Australasian
More informationREGULATORS PERSPECTIVE ON ALLERGEN MANAGEMENT IN THE FOOD INDUSTRY
REGULATORS PERSPECTIVE ON ALLERGEN MANAGEMENT IN THE FOOD INDUSTRY IFST CONFERENCE, CAMPDEN BRI 7-8 APRIL 2011 Sue Hattersley Head of Food Allergy Branch UK Food Standards Agency Overview Background on
More informationChair and members of the Board of Health. Jessica Morris, Manager, Environmental Health. Christopher Beveridge, Director, Health Protection
HEALTHY MENU CHOICES ACT TO: Chair and members of the Board of Health MEETING DATE: December 6, 2017 REPORT NO: Pages: 6 PREPARED BY: APPROVED BY: SUBMITTED BY: Jessica Morris, Manager, Environmental Health
More informationLeander ISD Food Allergy Management Plan (FAMP)
Leander ISD Food Allergy Management Plan (FAMP) Leander ISD s food allergy management plan has been developed according to Texas Education Code, EDUC 38.0151. Anaphylaxis is a sudden, severe, and potentially
More informationPeet's Coffee & Tea, Inc. Reports 62% Increase in Second Quarter 2008 Diluted Earnings Per Share
Peet's Coffee & Tea, Inc. Reports 62% Increase in Second Quarter 2008 Diluted Earnings Per Share EMERYVILLE, Calif., July 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peet's Coffee & Tea,
More informationFinding a Path to Safety in Food Allergy Highlights of the Consensus Report
Finding a Path to Safety in Food Allergy Highlights of the Consensus Report 1 Disclosure Report of The National Academies of Sciences This activity was supported by Federal Sponsors: The Food and Drug
More informationObjectives. 1 st half: 2 nd half:
Ask the Allergist Edmond S. Chan, MD, FRCPC Clinical Associate Professor, UBC Division of Allergy & Immunology June 14, 2014 Metro Vancouver Anaphylaxis Group Burnaby Objectives 1 st half: Discuss: How
More informationFOOD ALLERGY AND MEDICAL CONDITION ACTION PLAN
CAMPUS DINING AT HOLY CROSS COLLEGE FOOD ALLERGY AND MEDICAL CONDITION ACTION PLAN Accommodating Individualized Dietary Requirements Including Food Allergies, Celiac Disease, Intolerances, Sensitivities,
More informationMedical Conditions Policy
Medical Conditions Policy Background: Anaphylaxis is a severe, life-threatening allergic reaction. Up to two per cent of the general population and up to 5 percent of young children (0-5yrs) are at risk.
More informationFood Management Food Allergy Policy Guidance
` Opaa! Food Management Food Allergy Policy Guidance A special report to Opaa! s Partners regarding our policy for dealing with Special Dietary Needs and Food Allergies It is the opinion of allergy medical
More informationAdvances in Pediatric Food Allergy
Advances in Pediatric Food Allergy Case-based Discussions on Diagnosis and Management Course Director Sponsored by Department of Pediatrics Icahn School of Medicine at Mount Sinai, New York December 1,
More informationGENERAL DESCRIPTION OF INDUSTRY AND COMPANY
Appendix G Appendix Sample G: Import Business Business Plan: Otoro Plan: Import Company Otoro Import Company EXECUTIVE SUMMARY Otoro Imports is a spice importing and marketing corporation established in
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationDOWNLOAD OR READ : ANAPHYLAXIS IN SCHOOLS OTHER SETTINGS 3RD EDITION PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : ANAPHYLAXIS IN SCHOOLS OTHER SETTINGS 3RD EDITION PDF EBOOK EPUB MOBI Page 1 Page 2 anaphylaxis in schools other settings 3rd edition anaphylaxis in schools other pdf anaphylaxis in
More informationPreliminary unaudited financial results for the full year ended 30 June Amount for this reporting period
Marlborough Wine Estates Group Limited Results for Announcement to the Market Preliminary unaudited financial results for the full year ended 30 June 2017 Reporting Period 1st July to 30th June 2017 Previous
More informationWeily Soong, MD Board Certified in Allergy & Clinical Immunology
Weily Soong, MD Dr. Weily Soong is a native of Birmingham, and graduated from Vestavia Hills High School, Birmingham-Southern College, and the University of Alabama School of Medicine. He completed his
More informationJennings Street School
Anaphylaxis Management Policy Anaphylaxis is a severe, rapidly progressive allergic reaction that is potentially life threatening. The most common allergens in school aged children are peanuts, eggs, tree
More informationAllergies and Intolerances Policy
Allergies and Intolerances Policy 2016 2018 This policy should be read in conjunction with the following documents: Policy for SEND/Additional Needs Safeguarding & Child Protection Policy Keeping Children
More informationU.S. Retail Coffee. Joe Stanziano Senior Vice President and General Manager, Coffee
U.S. Retail Coffee Joe Stanziano Senior Vice President and General Manager, Coffee 1 Our Coffee Vision Build BELOVED COFFEE BRANDS that ignite the senses and inspire passions every day. OUR STRATEGIC PRIORITIES
More information2017 National Sponsorship OpportunitieS
2017 National Sponsorship OpportunitieS FAREWALK.ORG Food Allergy Research & Education (FARE) foodallergy.org FARE s FOOD ALLERGY HEROES WALK Food Allergy Research & Education (FARE) s
More informationAllergy Management Policy
Allergy Management Policy Awareness in the Classrooms All Saints Catholic School 48735 Warren Road Canton, MI 48187 734-459-2490 Information and Guidelines For School and Parents All Saints Catholic School
More informationObesity Prevention at the State and Local Levels: Lessons Learned and New Opportunities
Public Health Practice Grand Rounds Obesity Prevention at the State and Local Levels: Lessons Learned and New Opportunities Lainie Rutkow, JD, PhD, MPH Johns Hopkins Bloomberg School of Public Health August
More informationPizza Pizza Royalty Corp. ANNUAL GENERAL MEETING May 29, 2013
Pizza Pizza Royalty Corp. ANNUAL GENERAL MEETING May 29, 2013 1 Elizabeth Wright, Board Chair 2 Forward-Looking Statement This presentation will contain forward-looking statements. Investors should be
More informationFood Allergy. Allergy and Immunology Awareness Program
Food Allergy Allergy and Immunology Awareness Program Food Allergy Allergy and Immunology Awareness Program What is a food allergy? A food allergy is when your body s immune system reacts to a food protein
More informationPartnerships between schools and parents are important in ensuring that certain foods or items are kept away from the student while at school.
Anaphylaxis Policy CONTEXT Anaphylaxis is a severe, rapidly progressive allergic reaction that is life threatening. The most common allergens for school-aged children are peanuts, eggs, tree nuts (e.g.
More informationCLINICAL AUDIT. Appropriate prescribing of specialised infant formula for cows milk protein allergy
CLINICAL AUDIT Appropriate prescribing of specialised infant formula for cows milk protein allergy Valid to December 2019 bpac nz better medicin e Background Specialised infant formulae subsidised on the
More informationCitation for published version (APA): Goossens, N. (2014). Health-Related Quality of Life in Food Allergic Patients: Beyond Borders [S.l.]: s.n.
University of Groningen Health-Related Quality of Life in Food Allergic Patients Goossens, Nicole IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationand the World Market for Wine The Central Valley is a Central Part of the Competitive World of Wine What is happening in the world of wine?
The Central Valley Winegrape Industry and the World Market for Wine Daniel A. Sumner University it of California i Agricultural l Issues Center January 5, 211 The Central Valley is a Central Part of the
More informationThe concept of thresholds: do safe doses exist for food-allergic patients? Professor Katie Allen, MBBS, BMedSc, FRACP, FAAAAI, PhD Director,
The concept of thresholds: do safe doses exist for food-allergic patients? Professor Katie Allen, MBBS, BMedSc, FRACP, FAAAAI, PhD Director, Population Health Murdoch Childrens Research Institute Royal
More informationMichael Sheridan BSc., BEd., DipFinPl., GradDipEnvHth., MBiotech.
Current approaches in diagnosing and managing food allergy among Queensland Public Health settings Michael Sheridan BSc., BEd., DipFinPl., GradDipEnvHth., MBiotech. PhD RESEARCH CANDIDATE SUPERVISOR: A/PROF
More informationCustomer Focused, Science Driven, Results Led
Navigating allergen claims, labelling requirements and what they actually mean for manufacturers Simon Flanagan Senior Consultant Food Safety and Allergens Customer Focused, Science Driven, Results Led
More informationPrecautionary Allergen Labelling. Lynne Regent Anaphylaxis Campaign
Precautionary Allergen Labelling Lynne Regent Anaphylaxis Campaign CEO @LynneRegentAC About the Anaphylaxis Campaign The only UK wide charity solely focused on supporting people at risk of severe allergic
More informationUnilever and tea sustainability. The World of Tea
Unilever and tea sustainability Michiel Leijnse, Global Brand Development Manager Lipton This presentation may contain forward-looking statements, including 'forward-looking statements' within the meaning
More informationAquarium of the Pacific Food Allergy and Anaphylaxis Protocol
Aquarium of the Pacific Food Allergy and Anaphylaxis Protocol Purpose Statement: The Aquarium of the Pacific recognizes the increasing prevalence of allergies in children, including many life threatening
More informationEnquiring About Tolerance (EAT) Study. Randomised controlled trial of early introduction of allergenic foods to induce tolerance in infants
Enquiring About Tolerance (EAT) Study Randomised controlled trial of early introduction of allergenic foods to induce tolerance in infants Final version 20/08/2012 STATISTICAL ANALYSIS PLAN FOR MAIN PAPER
More informationCarole Bingley Customer Focused, Science Driven, Results Led
Overview of the Plant-Based Sector Market Trends Carole Bingley Customer Focused, Science Driven, Results Led Overview Introduction to RSSL Vegan/vegetarian/flexitarian diets setting the scene Labelling
More informationREVISED 04/10/2018 Page 1 of 7 FOOD ALLERGY MANAGEMENT PLAN
GARLAND INDEPENDENT SCHOOL DISTRICT HEALTH SERVICES Food Allergy Management Plan DEFINITIONS FOOD INTOLERANCE ALLERGIC REACTION SEVERE FOOD ALLERGY ANAPHYLACTIC REACTION FOOD ALLERGY MANAGEMENT PLAN (FAMP)
More informationPRODUCT REGISTRATION: AN E-GUIDE
PRODUCT REGISTRATION: AN E-GUIDE Introduction In the EU, biocidal products are only allowed on the market if they ve been authorised by the competent authorities in the Member States in which they will
More information1156 Fifteenth Street, NW Suite 200 Washington, DC 20005
1156 Fifteenth Street, NW Suite 200 Washington, DC 20005 1.202.659.0074 voice 1.202.659.3859 fax www.ilsina.org Good afternoon, I m Alison Kretser, Director of Science Programs at ILSI North America. The
More informationThe Growing Concern Around Allergens: Protecting Your Customers
The Growing Concern Around Allergens: Protecting Your Customers Mike Spigler, MCHES VP of Education Food Allergy Research & Education (FARE) Conference on Food Protection May 15, 2013 About Food Allergy
More informationOral food immunotherapy/desensitization
Oral Immunotherapy and Anti-IgE Antibody- Adjunctive Treatment for Food Allergy: Omalizumab facilitates oral desensitization in high-risk peanut allergy patients Dale T. Umetsu, MD, PhD The Prince Turki
More informationKaren Lapsley, ABC Chief Scientific Officer
Karen Lapsley, ABC Chief Scientific Officer Mary Wagner, Starbucks Coffee Company Product Innovation at Starbucks Mary Wagner, Ph.D Mary K. Wagner, Ph.D SVP, Global R&D/Quality, Food Safety & Regulatory
More informationHydrolyzed & plant-based formulas
Hydrolyzed & plant-based formulas How the game is changing Einerhand Science & Innovation Website: www.esi4u.nl E-mail: info@esi4u.nl How the infant formula landscape is changing Hydrolyzed formula Infant
More information: Sumadiono, dr SpA(K) Place/date of birth : Nganjuk, : Staff of Pediatric Dept.UGM Yogyakarta
CURRICULUM VITAE Name : Sumadiono, dr SpA(K) Place/date of birth : Nganjuk, 9-10-1956 Occupation : Staff of Pediatric Dept.UGM Yogyakarta Educations : General Doctor : Fac. Of Medicine Unair, Surabaya,
More informationFood Allergy Management:
Food Allergy Management: Myths & Facts Monday, July 9, 2018 8-9 a.m. Speaker Slide Sherry Coleman Collins Registered Dietitian Nutritionist, Consultant Jessica Gerdes Registered Nurse School Nurse Consultant
More informationANAPHYLAXIS POLICY. This policy was last ratified by School Council on March 2014
ANAPHYLAXIS POLICY This policy was last ratified by School Council on March 2014 RATIONALE Anaphylaxis is a severe rapidly progressive allergic reaction that is potentially life threatening and requires
More information1) What proportion of the districts has written policies regarding vending or a la carte foods?
Rhode Island School Nutrition Environment Evaluation: Vending and a La Carte Food Policies Rhode Island Department of Education ETR Associates - Education Training Research Executive Summary Since 2001,
More informationFrontiers in Food Allergy and Allergen Risk Assessment and Management. 19 April 2018, Madrid
Frontiers in Food Allergy and Allergen Risk Assessment and Management 19 April 2018, Madrid Food allergy is becoming one of the serious problems of China's food safety and public health emergency. 7 Number
More informationThe Section on Pediatrics-EAACI has currently around 1000 members with voting rights.
Section on Pediatrics, EAACI 2009 2010 Annual Report Board members: Susanne Halken, Chair of the Section Graham Roberts, Secretary of the Section Susanne Lau, Member Angel Mazon Ramos, Webmaster of the
More informationOntario Bean Growers. General Manager s Report 2015
Ontario Bean Growers General Manager s Report 2015 A successful first year Priorities set by committees of the board Research, Market Development, Governance and Finance & Audit Based on the strategic
More informationFood Allergen Labeling and Consumer Protection Act of 2004
FDA Home Page CFSAN Home Search/Subject Index Q & A Help August 2, 2004 Food Allergen Labeling and Consumer Protection Act of 2004 (Title II of Public Law 108-282) (This document also available in PDF)
More informationNetworkers Business Update. December 2014
Networkers Business Update December 2014 Agenda Forecast Milk Price Global markets V3 Strategy Growing our share of New Zealand milk Page 2 Forecast Milk Price 110 100 2012/13 2013/14 2014/15 Forecast
More informationAnaphylaxis Management in the School Setting
Anaphylaxis Management in the School Setting Keeping Children Safe Anita Wheeler, RN, MSN School Health Coordinator/Nurse Consultant anita.wheeler@dshs.state.tx.us 1 Learning Objectives The learner will
More informationSt Francis Xavier Primary School Anaphylaxis Management Policy
St Francis Xavier Primary School Anaphylaxis Management Policy Reviewed: February 2015 Ratified: March 2015 Next Review: 2019 RATIONALE: Anaphylaxis is a severe, rapidly progressive allergic reaction that
More informationFOOD ALLERGY PROTOCOL
FOOD ALLERGY PROTOCOL Kerby is dedicated to keeping students with food allergies safe in the school environment. There is no one way to manage food allergies and each student s situation needs careful
More informationFONTERRA AT A GLANCE
FONTERRA AT A GLANCE AN INTRODUCTION TO FONTERRA We re united by a fundamental belief in the power of dairy to make a difference. WE RE A GLOBAL DAIRY NUTRITION COMPANY A CO-OPERATIVE OWNED BY 10,500
More informationREMARKS BY PAUL BULCKE, GROUP CHIEF EXECUTIVE OFFICER, NESTLÉ S.A. MEDIA CONFERENCE, NAIROBI, FRIDAY, JULY 2, 2010
REMARKS BY PAUL BULCKE, GROUP CHIEF EXECUTIVE OFFICER, NESTLÉ S.A. MEDIA CONFERENCE, NAIROBI, FRIDAY, JULY 2, 2010 Disclaimer This speech might not reflect absolutely all exact words spoken. This speech
More informationGluten regulations frequently asked questions
Gluten regulations frequently asked questions Commission Regulation 41/2009 concerning the composition and labelling of foodstuffs suitable for people intolerant to gluten (coeliacs) Know the rules Factual
More informationSoyfoods Association of North America th Street, NW Suite 600 Washington, DC USA
Soyfoods Association of North America 1050 17 th Street, NW Suite 600 Washington, DC 20036 USA April 19, 2013 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm.
More informationFoodservice EUROPE. 10 countries analyzed: AUSTRIA BELGIUM FRANCE GERMANY ITALY NETHERLANDS PORTUGAL SPAIN SWITZERLAND UK
Foodservice EUROPE MARKET INSIGHTS & CHALLENGES 2015 2016 2017 2020 Innovative European Foodservice Experts 18, avenue Marcel Anthonioz BP 28 01220 Divonne-les-Bains - France 10 countries analyzed: AUSTRIA
More informationGrowing Trade & Expanding Markets. Presentation to the Canadian Horticultural Council Trade and Marketing Committee Fred Gorrell March 14, 2018
Growing Trade & Expanding Markets Presentation to the Canadian Horticultural Council Trade and Marketing Committee Fred Gorrell March 14, 2018 Outline Sector Snapshot Export Trends & Opportunities Trade
More informationMelbourne University Sport Anaphylaxis Policy
Melbourne University Sport Anaphylaxis Policy The safety and well-being of children is of prime importance at Melbourne University Sport Programs. All reasonable steps will be taken to ensure the safety
More informationReport No. 3 of the Health and Emergency Medical Services Committee Regional Council Meeting of April 27, SABRINA'S LAW
1 SABRINA'S LAW The Health and Emergency Medical Services Committee recommends the adoption of the recommendation contained in the following report, March 9, 2006, from the Commissioner of Community Services,
More informationOUR POTENTIAL. Business Update MAY 2017
OUR POTENTIAL Business Update MAY 2017 Disclaimer This presentation may contain forward-looking statements and projections. There can be no certainty of outcome in relation to the matters to which the
More informationAllergy and Anaphylaxis Policy
Statement This policy serves to promote an allergy aware community. At Splash Centre we have recognised the need to adopt a policy on allergies that may be present in the children who attend our centre.
More informationAllergy Awareness and Management Policy
Allergy Awareness and Management Policy Overview This policy is concerned with a whole school approach to the health care management of those members of our school community suffering from specific allergies.
More informationRECOMMENDED PROTOCOL
RECOMMENDED PROTOCOL St. Thecla is dedicated to keeping students with food allergies safe in the school environment. There is no one way to manage food allergies and each student s situation needs careful
More informationTungamah Primary School- No ANAPHYLAXIS POLICY
- No. 2225 ANAPHYLAXIS POLICY BACKGROUND: Anaphylaxis is a severe, rapidly progressive allergic reaction that is potentially life threatening. The most common allergens in school aged children are peanuts,
More informationFinancial Results for Fiscal Year Ending December 31, February 12, 2016 Suntory Beverage & Food Limited
2016 SUNTORY 2013 BEVERAGE SUNTORY BEVERAGE & FOOD & LIMITED. Limited. All Rights All Reserved Rights Reserved. Financial for Fiscal Year Ending December 31, 2015 February 12, 2016 Suntory Beverage & Food
More informationORAL FOOD CHALLENGE PARENT GUIDE
ORAL FOOD CHALLENGE PARENT GUIDE Your child is scheduled to have a food challenge. Small but increasing amounts of the food will be given to your child and we will be observing your child for any changes
More informationAllergen Pangan. Allergen Pangan
Allergen Pangan Isu Mutakhir dan Relevansinya bagi Industri Pangan di Indonesia Southeast Asian Food & Agricultural Science & Technology (SEAFAST) Center, And Dept of Food Science & Technology, Faculty
More informationClinical Immunology and Allergy Fellowship Program Kuwait Institute for Medical Specialization
Issued: June, 2011 Clinical Immunology and Allergy Fellowship Program Kuwait Institute for Medical Specialization I. INTRODUCTION The primary aim of the Allergy and Clinical Immunology Fellowship Program
More informationGUIDANCE ON THE DIAGNOSIS AND MANAGEMENT OF LACTOSE INTOLERANCE AND PRESCRIPTION OF LOW LACTOSE INFANT FORMULA.
GUIDANCE ON THE DIAGNOSIS AND MANAGEMENT OF LACTOSE INTOLERANCE AND PRESCRIPTION OF LOW LACTOSE INFANT FORMULA. These are the lactose intolerance guidelines and it is recommended that they are used in
More informationThe Epicutaneous Immunotherapy Company
The Epicutaneous Immunotherapy Company December 2018 Genoskin Safe Harbor This presentation contains forward looking statements including, but not limited to, statements concerning the outcome or success
More informationWork Sample (Minimum) for 10-K Integration Assignment MAN and for suppliers of raw materials and services that the Company relies on.
Work Sample (Minimum) for 10-K Integration Assignment MAN 4720 Employee Name: Your name goes here Company: Starbucks Date of Your Report: Date of 10-K: PESTEL 1. Political: Pg. 5 The Company supports the
More informationPaper Reference IT Principal Learning Information Technology. Level 3 Unit 2: Understanding Organisations
Centre No. Candidate No. Surname Signature Paper Reference(s) IT302/01 Edexcel Principal Learning Information Technology Level 3 Unit 2: Understanding Organisations Wednesday 3 June 2009 Morning Time:
More informationIDH Programs in Vietnam
IDH, The Sustainable Trade Initiative accelerates and up scales sustainable trade by building impact oriented coalitions of front running companies, civil society organizations, governments and other stakeholders.
More informationNut allergies. including peanuts
Nut allergies including peanuts What are allergies? An allergy is an over-reaction of the body's immune system to everyday things that should not normally bother people. Allergens, the substances that
More informationFood Triggers: The Degree of Avoidance
Food Triggers: The Degree of Avoidance Marion Groetch, MS, RDN marion.groetch@mssm.edu Director of Nutrition Services, Jaffe Food Allergy Institute Icahn School of Medicine American Academy of Allergy,
More informationFor personal use only
11 December 2013 FONTERRA MAINTAINS FORECAST FARMGATE MILK PRICE FOR 2013/14 SEASON AND CONTINUES INVESTING IN THE FUTURE Forecast Fonterra Co-operative Group Limited is maintaining its forecast Farmgate
More informationRichard Girardot chief Executive Officer. Vevey, December 2 nd, 2009
Richard Girardot chief Executive Officer Vevey, December 2 nd, 2009 Disclaimer This presentation contains forward looking statements which reflect Management s current views and estimates. The forward
More informationwertyuiopasdfghjklzxcvbnmqwertyui Holy Name Primary School opasdfghjklzxcvbnmqwertyuiopasdfg
qwertyuiopasdfghjklzxcvbnmqwerty uiopasdfghjklzxcvbnmqwertyuiopasd fghjklzxcvbnmqwertyuiopasdfghjklzx cvbnmqwertyuiopasdfghjklzxcvbnmq Anaphylactic Booklet wertyuiopasdfghjklzxcvbnmqwertyui Holy Name Primary
More information